You can read the full article at Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial Little is known about the effects of tirzepatide, a medication that stimulates both the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, when added to insulin glargine for treating type 2 diabetes
By extending the interval between doses, some individuals report reduced nausea or injection discomfort, though this trade-off typically results in less consistent appetite suppression
Insurance vs Cash-Pay Decision Matrix Try Insurance First If: Have commercial health insurance Insurance covers weight loss treatment BMI clearly meets criteria Willing to navigate prior authorization Can wait 4-8 weeks for approval Go Straight to Compounded If: No insurance Insurance doesnt cover weight loss Previously denied Medicare/Medicaid (cant cover) Want immediate access Prefer cash-pay simplicity Many patients try insurance, get denied, then switch to compoundedconsider starting with compounded to avoid delays
SURMOUNT-1 Trial (Jastreboff et al., 2022): Even at the 2.5 mg starting dose, participants achieved 16% weight loss
The changes in body weight were also notable, with the tirzepatide groups showing significant reductions compared to the placebo group
Month 1: Starter, no prior Rx needed Month 6+: Maintenance concentration All prices are pharmacy passthrough at Optimal Balance Pharmacy wholesale, no markup